Jon Stonehouse, BioCryst president and CEO
May 5, 2022 11:16 AM EDT
R&D
FDA+

BioCryst of­fi­cial­ly gets par­tial clin­i­cal hold on lead can­di­date af­ter halt­ing en­roll­ment

Paul Schloesser

Associate Editor

About a month af­ter BioCryst halt­ed three stud­ies for its oral Fac­tor D in­hibitor BCX9930, the FDA has im­posed a par­tial clin­i­cal hold.
The new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times